Compare PRAX & RGTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | RGTI |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.8B |
| IPO Year | 2020 | N/A |
| Metric | PRAX | RGTI |
|---|---|---|
| Price | $297.92 | $25.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $374.64 | $31.86 |
| AVG Volume (30 Days) | 586.2K | ★ 32.2M |
| Earning Date | 02-27-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,463,000.00 | ★ $7,494,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,827.76 | $167.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $5.95 |
| 52 Week High | $317.72 | $58.15 |
| Indicator | PRAX | RGTI |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 51.15 |
| Support Level | $266.93 | $23.93 |
| Resistance Level | $305.21 | $26.25 |
| Average True Range (ATR) | 15.96 | 1.67 |
| MACD | -3.30 | 0.41 |
| Stochastic Oscillator | 61.49 | 77.37 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.